{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:30Z","timestamp":1790696010456,"version":"4.1.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Peripheral T-cell lymphoma is a heterogenous non-Hodgkin Lymphoma with historically poor outcomes. Currently, response rates remain poor with traditional chemotherapy and many of those responding to initial therapy will relapse. Belinostat (Beleodaq, Spectrum Pharmaceuticals) is a histone deacetylase inhibitor (HDACi) approved for use in relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat is metabolized hepatically through cytochrome P-450 enzymes 3A4, 2C9, and 2A6; however, no empiric dosage adjustments of belinostat are recommended during concurrent use of inhibitors or inducers of these enzymes. Belinostat\u2019s efficacy has been evaluated in a clinical trial showing an overall response rate (ORR) of 25.8% and a median duration of response of 8.4 months. Belinostat is generally well tolerated, with the most common adverse reactions (&gt;25%) being nausea, vomiting, fatigue, pyrexia, and anemia in patients with relapsed or refractory PTCL. Belinostat is a safe and effective treatment option for relapsed and refractory peripheral T-cell lymphoma, with many future applications currently being investigated.<\/jats:p>","DOI":"10.1177\/1078155216634178","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T20:08:39Z","timestamp":1456517319000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":65,"title":["Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma"],"prefix":"10.1177","volume":"23","author":[{"given":"Peter","family":"Campbell","sequence":"first","affiliation":[{"name":"Department of Pharmacy, NewYork-Presbyterian Hospital, University Hospital of Columbia and Cornell, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christan M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NewYork-Presbyterian Hospital, University Hospital of Columbia and Cornell, New York, USA"},{"name":"Department of Clinical Health Professions, College of Pharmacy, St. John\u2019s University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"bibr1-1078155216634178","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008"},{"key":"bibr2-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"bibr3-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.08.001"},{"key":"bibr4-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306"},{"key":"bibr5-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"bibr6-1078155216634178","doi-asserted-by":"publisher","DOI":"10.2146\/news140056"},{"key":"bibr7-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0275-8"},{"key":"bibr8-1078155216634178","unstructured":"Beleodaq (Belinostat) package insert\n                      . Irvine, CA: Spectrum Pharmaceuticals, 2014."},{"key":"bibr9-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2007.01.001"},{"key":"bibr10-1078155216634178","unstructured":"SOLVO-TopoTarget-01. In\u00a0vitro interaction studies of one test article with P-gp (MDR1\/ABCB1) in the vesicular transport assay and in Bidirectional Transport (Papp) Studies on Caco-2 monolayers. Internal report 2010."},{"key":"bibr11-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222"},{"key":"bibr12-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-69"},{"key":"bibr13-1078155216634178","unstructured":"Brentuximab vedotin (Adcetris) package insert\n                      . Bothell, WA: Seattle Genetics, 2015."},{"key":"bibr14-1078155216634178","unstructured":"Pralatrexate (Folotyn) package insert\n                      . Westminster, CO: Allos Therapeutics, 2011."},{"key":"bibr15-1078155216634178","first-page":"4916","volume":"62","author":"Furumai R","year":"2012","journal-title":"Cancer Res"},{"key":"bibr16-1078155216634178","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.3"},{"key":"bibr17-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.1291"},{"key":"bibr18-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1021\/jm0303094"},{"key":"bibr19-1078155216634178","unstructured":"National Comprehensive Cancer Network. Non-Hodgkin lymphoma (Version 2.2015). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf (accessed 12 April 2015)."},{"key":"bibr20-1078155216634178","unstructured":"ClinicalTrials.gov. Belinostat. http:\/\/clinicaltrials.gov\/ct2\/results?term=belinostat&Search=Search (accessed 13 April 2015)."},{"key":"bibr21-1078155216634178","doi-asserted-by":"crossref","unstructured":"Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors.\n                      Arch Pharm Res\n                      2015. Epub ahead of print.","DOI":"10.1007\/s12272-015-0571-1"},{"key":"bibr22-1078155216634178","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.25941"},{"key":"bibr23-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.016"},{"key":"bibr24-1078155216634178","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.877134"},{"key":"bibr25-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000122"},{"key":"bibr26-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077684"},{"key":"bibr27-1078155216634178","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Daugaard G, Lesimple T, et\u00a0al. Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.\n                      Cancer\n                      2015. Epub ahead of print.","DOI":"10.1002\/cncr.29229"},{"key":"bibr28-1078155216634178","doi-asserted-by":"crossref","unstructured":"Kim MJ, Lee JS, Park SE, et\u00a0al. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: A role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.\n                      J Urol\n                      2014. Epub ahead of print.","DOI":"10.1016\/j.juro.2014.11.091"},{"key":"bibr29-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0968"},{"key":"bibr30-1078155216634178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.019"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216634178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216634178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216634178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:41Z","timestamp":1777688201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216634178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1078155216634178"],"URL":"https:\/\/doi.org\/10.1177\/1078155216634178","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}